Nexus BioPharma, Inc., (OTC-BB: NEXS), a company specializing in the development of a weight loss drug therapy, announced today the appointment of Helen Stefanovic as Director of Regulatory Affairs. Ms. Stefanovic has broad and extensive experience in all aspects of the FDA drug approval process and has worked on product approvals in endocrinology, biologics, biosimilars, vaccines & anti-infectives, and oncology. She served as Manager, Science Policy, Corporate Strategic Planning and Policy at Pfizer Inc, World Headquarters. Previously she was Project Leader, Regulatory Affairs, Bristol-Myers Squibb Canada. She began her career in regulatory affairs at Sandoz, Canada where she was instrumental in the successful registration of the key products SANDIMMUNE™ and NEORAL™. Ms. Stefanovic earned a B.Sc. Biological Sciences at Concordia University, Montreal, Quebec and a M.Sc. Microbiology & Immunology at the University of Ottawa, Ontario.

Warren C. Lau, President and CEO of Nexus stated, "We are pleased to have Helen on board. She has the expertise and experience to plan the company's pre-IND program and push toward our goal of commencing human clinical trials before the end of next year."

"I am looking forward to the challenge of bringing this important life-changing product to the market in the most expeditious time frame possible," said Stefanovic. "We will be exploring all avenues that might include Orphan Drug Designation for Prader Willi Syndrome, as well as Accelerated Approval Pathway, Breakthrough and Fast Track Designation to compress the timeline."

About Nexus BioPharma, Inc. www.nexusbiopharma.com

Nexus BioPharma, Inc. is developing a new weight loss drug that works differently than any currently available prescription drug. It adjusts the body's metabolism to increase the burning of fat by activating the AMPK metabolic pathway, the same pathway activated by intense physical exercise.